Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Celgene
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A clinical trial to evaluate if apremilast is safe in children and adolescents with moderate to severe plaque psoriasis as well as assessing how apremilast is processed by the body, and to determine the appropriate dose for them
The primary objective of the study is to select a pediatric dose of apremilast based on the safety, tolerability, and PK of apremilast in adolescents and children with moderate to severe plaque psoria...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to systemic anticancer therapy
To evaluate the efficacy of CC-4047
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Abraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation
Update Il y a 4 ans
Clinical study for patients with breast cancer that has spread to other parts of the body and that does not respond to hormonal or anti-HER2 therapy ('triple negative disease'), comparing a chemotherapy treatment (carboplatin + gemcitabine) with an experimental treatment of nab-paclitaxel plus chemotherapy (carboplatin OR gemcitabine)
- Phase 2: evaluate the benefit and risk profiles of the two nab-paclitaxel experimental arms and identify the nab-paclitaxel combination that will be used in the Phase 3. - Phase 3: compare the p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A phase 2, randomized, open-label, parallel, study with sotatercept in patients with anemia and low or intermediate-1 risk myelodysplastic syndromes or non-proliferative chronic myelomonocytic leukemia
The primary objective of this study is to determine a safe, tolerable and effective dose of sotatercept that results in the greatest frequency of erythroid hematological improvement (HI-E) in patients...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Celgene Corporation
Update Il y a 4 ans
A clinical trial to see if the combination CC-486 plus fulvestrant is effective and safe, compared to fulvestrant alone, in patients with metastatic breast cancer that is estrogen receptor-positive and human epidermal growth factor receptor 2-negative
To evaluate the efficacy of CC-486 in combination with fulvestrant relative to fulvestrant monotherapy, by estimation of the hazard ratio of progression free survival (PFS)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Max and 25 years
Celgene
Update Il y a 5 ans
Étude JCAR017-BCM-004 : étude de phase 1b-2 évaluant la sécurité et l’efficacité du lisocabtagene maraleucel chez des enfants ayant une leucémie aigüe lymphoblastique à cellules B ou un lymphome non hodgkinien à cellules B, récidivant ou réfractaire.
Les hémopathies malignes regroupent un ensemble de cancers des cellules sanguines et de leurs précurseurs comme les leucémies et les lymphomes. Les cellules souches hématopoïétiques sont fabriquées pa...
Country
France
organs
Leucémies aiguës
,
Lymphomes non hodgkinien
Specialty
Pédiatrie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with Beta-Thalassemia who require regular red blood cell tranfusions
The primary objective of the study is: - To determine the proportion of subjects treated with luspatercept plus BSC versus placebo plus BSC who achieved erythroid response, defined as ≥ 33% reduction...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 4 ans
Étude CC-220-MM-001 : étude de phase 1b-2a évaluant la sécurité, la tolérance, la pharmacocinétique et l’efficacité du CC-220 en monothérapie et en association avec de la dexaméthasone chez des patients ayant un myélome multiple en rechute ou réfractaire.
Le myélome multiple est une maladie de la moelle osseuse caractérisée par la multiplication dans la moelle osseuse d’un plasmocyte anormal. Le rôle des plasmocytes est de produire les anticorps (immun...
Country
France
organs
Myélomes
Specialty
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Celgene Corporation
Update Il y a 4 ans
A large clinical study, for patients who have recently undergone surgery to remove some cancerous tissue from the pancreas, to compare post surgery treatment using nab-Paclitaxel and Gemcitibine or Gemcitibine alone
To compare disease-free survival (DFS) between subjects randomized to nabpaclitaxel in combination with gemcitabine and subjects randomized to gemcitabine alone
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Celgene
Update Il y a 4 ans
Étude CC-90010-ST-001 : étude de phase 1 évaluant la sécurité, l’efficacité, la tolérance et la pharmacocinétique du CC-90010, chez des patients ayant une tumeur solide avancée ou un lymphome non hodgkinien récidivant / réfractaire.
Les tumeurs solides sont l’ensemble des cancers qui se développent dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90% des cancers ...
Country
France
organs
Lymphomes non hodgkinien
,
Tumeurs solides
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next